Advertisement

Drugs

, Volume 79, Issue 17, pp 1839–1848 | Cite as

Immunotherapy Against Gliomas: is the Breakthrough Near?

  • Rimas V. LukasEmail author
  • Derek A. Wainwright
  • Craig M. Horbinski
  • Fabio M. Iwamoto
  • Adam M. Sonabend
Review Article

Abstract

Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of immunotherapies in other malignancies as well as the incremental gains in our understanding of immune-tumour interactions in gliomas has fuelled a strong continued interest of their evaluation in these tumours. We discuss a range of immunotherapeutic approaches including, but not limited to, vaccines, checkpoint inhibitors, oncolytic viruses, and gene therapies. Potential biomarkers under investigation to help elucidate which patients may respond or not respond to immunotherapeutic regimens are reviewed. Directions for future investigations are also noted.

Notes

Compliance with Ethical Standards

Funding

RVL, DAW, CMH, AMS are supported by P50CA221747 SPORE for Translational Approaches to Brain Tumours. DAW and RVL are supported by BrainUp grant 2136.

Conflicts of interest

RVL has received honoraria for serving on advisory boards for Monteris and Ziopharm. RVL, CMH, AMS, and FMI have received honoraria as consultants for Abbvie. FMI has received honoraria for consulting for Merck, Novocure, Tocagen, Alexion, and Regeneron. RVL has received support from Roche for travel to present at a meeting. FMI has received travel support to FDA meeting from Merck. FMI has received funding for research support for investigator-initiated trials from Merck, BMS, and Novocure. RVL have received honoraria for medical editing from Medlink Neurolology, medical review of content for EBSCO Publishing, and creating/presenting board review material for American Physician Institute.

References

  1. 1.
    Lukas RV, Mrugala MM. Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. Neuro Oncol Pract. 2017;4(4):209–19.Google Scholar
  2. 2.
    Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R. Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park). 2019;33(3):623491.PubMedGoogle Scholar
  3. 3.
    Mrugala MM, Ruzevick J, Zlomanczuk P, Lukas RV. Tumor treating fields in neuro-oncological practice. Curr Oncol Rep. 2017;19(8):53.PubMedGoogle Scholar
  4. 4.
    Kim WJ, Dho YS, Ock CY, et al. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma. J Neurooncol. 2019;143(2):321–8.PubMedGoogle Scholar
  5. 5.
    Chongsathidkiet P, Jackson C, Koyama S, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9):1459–68.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Huang J, DeWees TA, Badiyan SN, et al. Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys. 2015;92(5):1000–7.PubMedGoogle Scholar
  7. 7.
    Lin AJ, Campian JL, Hui C, et al. Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol. 2018;136(2):403–11.PubMedGoogle Scholar
  8. 8.
    Campian JL, Piotrowski AF, Ye X, et al. Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. J Neurooncol. 2017;135(2):343–51.PubMedGoogle Scholar
  9. 9.
    Grossman SA, Ellsworth S, Campian J, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Cancer Netw. 2015;13(10):1225–31.Google Scholar
  10. 10.
    Mendez JS, Govindan A, Leong J, Gao F, Huang J, Campian JL. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol. 2016;127(2):329–35.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Hegi ME, Stupp R. Witholding temozlomide in glioblastoma patients with unmethylated MGMT promoter—still a dilemma? Neuro Oncol. 2015;17(11):1425–7.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324–33.PubMedGoogle Scholar
  13. 13.
    Weller M, Butowski N, Tran DD, et al. Rindopepimut and temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–85.PubMedGoogle Scholar
  14. 14.
    Cloughesy TF, Mochizuki AY, Oprilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–86.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019;25(3):470–6.PubMedGoogle Scholar
  16. 16.
    Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozlomide-associated hypermutation in gliomas. Neuro Oncol. 2018;20(10):1300–9.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Van Thuijl HF, Mazor T, Johnson BE, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129(4):597–607.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Di Tomaso T, Mazzoleni S, Wang E, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16(3):800–13.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Wu A, Wiesner S, Xiao J, et al. Expression of MHC I and NK ligands on human CD133 + glioma cells: possible targets of immunotherapy. J Neurooncol. 2007;83(2):133.Google Scholar
  20. 20.
    Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139(Part 5):1458–71.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Giles AJ, Hutchinson MND, Sonnemann HM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin 12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019;11(505):eaaw5680.PubMedGoogle Scholar
  23. 23.
    Saito T, Sugiyama K, Hama S, et al. Prognostic importance of temozolomide-induced neutropenia in glioblastoma. IDH-wildtype patients. Neurosurg Rev. 2018;41(2):621–8.PubMedGoogle Scholar
  24. 24.
    Bambury RM, Teo MY, Power DG, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol. 2013;114(1):149–54.PubMedGoogle Scholar
  25. 25.
    Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611–8.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Back M, Jayamane D, Brazier D, et al. Tumor volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. J Clin Neurosci. 2019;59:68–74.PubMedGoogle Scholar
  27. 27.
    Ladomersky E, Zhai L, Lenzen A, et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res. 2018;24(11):2559–73.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Zhang D, Qiu B, Wang Y, Guan Y, Zhang L, Wu A. Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells. Cell Biol Int. 2017;41(6):680–90.PubMedGoogle Scholar
  29. 29.
    Galluzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714.Google Scholar
  30. 30.
    Kirson ED, Giladi M, Gurvich Z, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633–40.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Voloshin T, Yitzhaki OT, Kaynan N, et al. Tumor treating fields (TTFields) plus anti-PD-1 therapy induce immunogenic cell death resulting in enhanced antitumor efficacy. AACR abstract 3665. Cancer Res. 2017;77(13):3665.Google Scholar
  32. 32.
    Ladomersky E, Genet M, Zhai L, et al. Improving vaccine efficacy against malignant glioma. Oncoimmulogy. 2016;5(8):e1196311.Google Scholar
  33. 33.
    Weller M, Roth P, Preusser M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017;13(6):363–74.PubMedGoogle Scholar
  34. 34.
    Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II single-arm trial. Neuro Oncol. 2014;16(2):274–9.PubMedGoogle Scholar
  35. 35.
    Bloch O, Shi Q, Anderson SK, et al. ATIM-14. Alliance A071101: a phase 2 randomized trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96)vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma. Neuro Oncol. 2017;19(suppl_6):vi29.PubMedCentralGoogle Scholar
  36. 36.
    Liau LM, Ashkan A, Tran KDD, et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):142.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Liau LM, Ashkan K, Tran DD, et al. Correction to: First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):179.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Johanns TM, Bowman-Kirigin JA, Liu C, Dunn GP. Targeting neoantiegns in glioblastoma: an overview of cancer immunogenomics and translational implications. Neurosurgery. 2017;64(CN_suppl_1):165–76.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase 1b glioblastoma trial. Nature. 2019;565(7738):234–9.PubMedGoogle Scholar
  40. 40.
    Reardon DA, Schuster J, Tran DD, et al. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J Clin Oncol. 2015;33(15_suppl):2009.Google Scholar
  41. 41.
    Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–5.PubMedGoogle Scholar
  42. 42.
    Platten M, Schilling D, Bunse L, et al. NOA-16: A first-in-man multicenter phase 1 clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDHR132H in patients with newly diagnosed malignant astrocytomas ATIM-33. Neuro Oncol. 2018;20(suppl_6):vi8–9.PubMedCentralGoogle Scholar
  43. 43.
    Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumor immunity. Nature. 2014;512(7514):324–7.PubMedGoogle Scholar
  44. 44.
    Reardon DA OA, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, De Sousa P, Ahluwalia MS, Lim M, Vlahovic G, Sampson J. Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncology. 2017;19(Suppl. 3):iii21.PubMedCentralGoogle Scholar
  45. 45.
  46. 46.
  47. 47.
    Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Lukas RV, Rodon J, Becker K, et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018;140(2):317–28.PubMedGoogle Scholar
  49. 49.
    Johanns TM, Miller CA, Dorward IG, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–6.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841–9.PubMedGoogle Scholar
  51. 51.
    Panek WK, Kane JR, Young JS, et al. Hitting the nail on the head: combining adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. Oncotarget. 2017;8(51):89391–405.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–61.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (delta-24-RGD) oncoloytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–27.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Kloeppinger L, Amidei C, Lesniak M, et al. QOLP-11. Quality of life in high-grade glioma patients on a phase 1 virotheapy study. Neuro Oncol. 2018;20(suppl_6):vi216.PubMedCentralGoogle Scholar
  55. 55.
    Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD Jr, June CH. CAR-T cell therapies in glioblastoma. Clin Cancer Res. 2018;24(3):535–40.PubMedGoogle Scholar
  56. 56.
    Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy. Front Immunol. 2019;9:3062.PubMedPubMedCentralGoogle Scholar
  57. 57.
    O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506–18.PubMedGoogle Scholar
  59. 59.
    Joseph SK, Samaha H, Bielamowicz K, Ahmed N, et al. Response to the comment on “Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma” by Bielamowicz. Neuro Oncol. 2018;20(7):1004–5.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–9.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Goff SL, Morgan RA, Yang JC, et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42(4):126–35.PubMedGoogle Scholar
  62. 62.
    Van den Bent MJ, Gao Y, Kerkhof M, et al. Changes in the EGFR amplification and expression between paired primary and recurrent glioblastomas. Neuro Oncol. 2015;17(7):935–41.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Gresser I. Interferon and cancer: therapeutic prospects. Rev Eur Etud Clin Biol. 1970;15(1):23–7.PubMedGoogle Scholar
  64. 64.
    Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293–301.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7(4):486–98.PubMedGoogle Scholar
  66. 66.
    Dixit K, Kumthekar P. Gene delivery in neuro-oncology. Curr Oncol Rep. 2017;9(11):69.Google Scholar
  67. 67.
    Chiocca EA, Smith KM, McKinney B, et al. A phase 1 trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther. 2008;16(3):618–26.PubMedGoogle Scholar
  68. 68.
    Chiocca EA, Lukas R, Rao G, Barrett JA, Buck JY, Demars N, Smith A, Miao J, Zhou J, Gelb A, Cooper LJN. Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma. J Clin Oncol. 2019;37(15 suppl):2020.Google Scholar
  69. 69.
    Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018;20(10):1383–92.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Tocagen reports results of Toca 5 phase 3 trial in recurrent brain cancer. 2019. https://ir.tocagen.com/news-releases/news-release-details/tocagen-reports-results-toca-5-phase-3-trial-recurrent-brain. Accessed 12 Sept 2019.
  71. 71.
    Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195–205.PubMedGoogle Scholar
  72. 72.
    Pratt D, Dominah G, Lobel G, et al. Programmed death ligand 1 is a negative prognostic marker in recurrent isocitrate dehydrogenase-wildtype glioblastoma. Neurosurgery. 2019;85(2):280–89.PubMedGoogle Scholar
  73. 73.
    Gorsi HS, Malicki DM, Barsan V, et al. Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: a single institutional experience. J Pediatr Hematol Oncol. 2019;41(4):e235–41.PubMedGoogle Scholar
  74. 74.
    Larouche V, Atkinson J, Albrecht S, et al. Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. Pediatr Blood Cancer. 2018;65(12):e27389.PubMedGoogle Scholar
  75. 75.
    Zhao J, Chen AX, Gartell RD, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462–9.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–8.PubMedGoogle Scholar
  77. 77.
    Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.Google Scholar
  78. 78.
    Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5.PubMedGoogle Scholar
  79. 79.
    Vredenurgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15(12):1329–34.Google Scholar
  80. 80.
    Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139(Pt 5):1458–71.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018;13(11):1771–5.PubMedGoogle Scholar
  82. 82.
    Ladomersky E, Scholtens DM, Kocherginsky M, et al. The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma. Front Pharmacol. 2019;10:200.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflamm. 2019;16(1):53.Google Scholar
  84. 84.
    Otto-Meyer S, Lumibao J, Kim E, et al. The interplay among psychological distress, the immune system, and brain tumor patient outcomes. Curr Opin Behav Sci. 2019;28:44–50.PubMedGoogle Scholar
  85. 85.
    Kokolus KM, Capitano ML, Lee CT, et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci USA. 2013;110(50):20176–81.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Rimas V. Lukas
    • 1
    • 2
    Email author
  • Derek A. Wainwright
    • 2
    • 3
    • 4
    • 5
  • Craig M. Horbinski
    • 2
    • 3
    • 6
  • Fabio M. Iwamoto
    • 7
  • Adam M. Sonabend
    • 2
    • 3
  1. 1.Department of NeurologyNorthwestern UniversityChicagoUSA
  2. 2.Lou & Jean Malnati Brain Tumor Institute at the Lurie Comprehensive Cancer CenterNorthwestern UniversityChicagoUSA
  3. 3.Department of Neurological SurgeryNorthwestern UniversityChicagoUSA
  4. 4.Department of Microbiology-ImmunologyNorthwestern UniversityChicagoUSA
  5. 5.Department of Medicine-Hematology/OncologyNorthwestern UniversityChicagoUSA
  6. 6.Department of PathologyNorthwestern UniversityChicagoUSA
  7. 7.Department of NeurologyColumbia UniversityNew YorkUSA

Personalised recommendations